Altre lingue XOMA Royalty Corporation

Azioni

XOMA

US98419J2069

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 11/07/2024			Variaz. 5gg	Var. 1 gen.
26,18 ^USD	+1,95%		+1,08%	+41,51%

09/07	Xoma cambia nome in Xoma Royalty	MT
09/05	XOMA Corporation riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Xoma Changes Name to Xoma Royalty	09/07
XOMA Corporation(NasdaqGM:XOMA) added to Russell 3000 Growth Index	01/07
XOMA Corporation(NasdaqGM:XOMA) added to Russell Microcap Growth Index	01/07
XOMA Corporation(NasdaqGM:XOMA) added to Russell 3000E Growth Index	01/07
XOMA Corporation(NasdaqGM:XOMA) added to Russell 2000 Growth Index	01/07
XOMA Corporation(NasdaqGM:XOMA) added to Russell 2500 Growth Index	01/07
XOMA Corporation(NasdaqGM:XOMA) added to Russell Small Cap Comp Growth Index	01/07
XOMA Declares Quarterly Preferred Stock Dividends	20/06
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals Sale of its Priority Review Voucher	13/06
XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher	12/06
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher	12/06
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	14/05
Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	09/05
Xoma: Q1 Earnings Snapshot	09/05
XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	09/05
XOMA : 2024 Letter to Shareholders	09/05
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	30/04
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	30/04
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	25/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue XOMA Royalty Corporation

Azioni

XOMA

US98419J2069

Altre lingue

Filtri